|
Thursday, March 30, 2017 |
|
光大控股公布2016年度全年业绩 |
中国光大控股有限公司(下称「光大控股」,股份代号:165.HK)今天公布截至2016年12月31日止经审核之全年业绩。 more info >> |
|
光大控股公佈2016年度全年業績 |
中國光大控股有限公司(下稱「光大控股」,股份代號:165.HK)今天公佈截至2016年12月31日止經審核之全年業績。 more info >> |
|
China Everbright Limited announces FY2016 annual results |
China Everbright Limited ("CEL" or "the Group", 165.HK) today announced its audited annual results for the year ended 31 December 2016. more info >> |
|
Tuesday, November 8, 2016 |
|
光大控股投资项目贝达药业在深圳证券交易所创业板正式挂牌上市 |
中国光大控股有限公司(简称 “光大控股”,股份代码:165.HK)旗下医疗健康基金所投资的贝达药业股份有限公司(简称 “贝达药业”)在深圳证券交易所创业板正式挂牌上市,成为A股市场第一家新药公司,上市代码为300558。 more info >> |
|
光大控股投資項目貝達藥業在深圳證券交易所創業板正式掛牌上市 |
中國光大控股有限公司(簡稱「光大控股」,股份代碼:165.HK)旗下醫療健康基金所投資的貝達藥業股份有限公司(簡稱「貝達藥業」)在深圳證券交易所創業板正式掛牌上市,成為A股市場第一家新藥公司,上市代碼為300558。 more info >> |
|
Bettapharma, an Investment Project of China Everbright Limited, Listed on the ChiNext of Shenzhen Stock Exchange |
Betta Pharmaceuticals Co., Ltd. ("Bettapharma"), an investment project of China Everbright Limited ("CEL", stock code: 165.HK)'s Medical & Healthcare Fund, was listed on the ChiNext as the first listed innovative pharma company, with stock code: 300558. more info >> |
|
Friday, October 21, 2016 |
|
'Everbright-IDG Industrial Fund' Enters Third-Party Payment Market through Investment in China UMS |
'Everbright-IDG Industrial Fund' Jointly Launched by CEL and IDG Capital Enters Third-Party Payment Market through Investment in China UMS more info >> |
|
Everbright Investment Conference 2016: Leaders from the Investment Industry explore new frontiers in Alternative Asset Management |
Around 450 business leaders from the investment industry gathered to examine the future of alternative asset management at the Everbright Investment Conference 2016, hosted by China Everbright Limited ("CEL", 165.HK) in Qingdao today. more info >> |
|
光大控股举办2016投资年会: 投资界领袖携手展望另类资产管理新格局 |
由中国光大控股有限公司(“光大控股”,股份代号:165.HK)举办的“光大控股投资年会2016”今日在青岛举行。 more info >> |
|
光大控股舉辦2016投資年會: 投資界領袖攜手展望另類資產管理新格局 |
由中國光大控股有限公司(「光大控股」,股份代號:165.HK)舉辦的「光大控股投資年會2016」今日在青島舉行。 more info >> |
|
|
|